Current Health News Sources Need to Be Reliable

Having constant access to new information and current health news is an exciting part of modern life. But recently there have been a number of email hoaxes and internet scams that have resulted in a more cautious public when it comes to finding out the latest in health bulletins. Your best bet when searching for medical information online is a website that does not attempt to sell anything and does not require a paid membership to view the contents.Emails are still the number one source for medical misinformation. A rather disturbing email hoax that made the rounds recently told people that they were getting a virus from boxes mailed from a specific company. The company received endless calls asking about the “virus” and there were a number of people that not only called but asked where their boxes were, stating that they were clients of the company and willing to risk the imaginary virus in order to get the nonexistent box.Another unreliable source for current health news is any internet site that sells a product that is supposed to cure whatever terrible disease that the same site is stating is an epidemic. First the scam artists discuss in urgent tones a life threatening illness and then they claim that best cure is the medicine or equipment they are selling. Any medical information site that tries to scare you into buying something is not a good source of information.Some sites actually ask for money before they give you answers. Membership fees, answer fees, or access fees are all names for basically charging you for information that should be publicly available to all. Most medical information is available via search engines but it can be a bit laborious slogging through all the search engine results. It’s great to have one site that you can do a search on for a specific topic or just review current health news, but not if the purpose of the site is to make money off of you. There are several high quality websites that you can access that provide excellent medical information and news without charging you.Be sure and be cautious when looking for up to date medical news and information. Find a reliable website that does not charge you, and make sure that you take all email notifications with more than a grain of salt.

Explore Asset And Sales Finance Solutions With Your Bank

If you’re starting up a business, it can be hard to grasp the terminology you need in order to speak to your bank about funds; when it comes to discussing asset and sales finance, for instance, things can get tricky. It is, firstly, important to know what asset and sales finance is: a service through which banks help businesses obtain a range of equipment, including plant and machinery, commercial vehicles, IT equipment, office furniture and cars. Essentially, sales financing will help you get quick access to cash, while asset financing will help fund business equipment.Many banks offer several cost-effective and expedient sales financing solutions; and with such solutions, businesses can find enough working capital to be able to operate. Two sales financing solutions are factoring and invoice discounting. With factoring (recourse and non-recourse),up to 95% of the value of approved invoices can be advanced within a given period of time with the balance being paid on receipt. And while invoice discounting (also recourse and non-recourse) functions in a similar way, there is a crucial difference between the two: in factoring, the client’s customers are made aware of the bank’s involvement with the business; in invoice discounting they are not.Another method of sales financing used by many banks is stock finance; this allows you to release as much as 60% of the funds tied up in eligible stock through a completely flexible system. This will release finance that is usually not available for working capital needs.Asset financing solutions will help you gain assets in an economical way, without eating into your cash reserves. As with sales financing, banks will often offer a range of asset finance solutions to its business customers. Hire Purchase, for example, can help you acquire the asset you need right away, but payments can be spread across the life of the asset in question. This may also allow you to keep the asset at the end of your term for a particular fee. Operating Lease asset finance will allow you to benefit from a particular asset, while the bank itself takes on the risk of losing its value; the rental and return conditions for the asset are fixed at the outset.Many banks will offer a variety of asset finance products that cover the needs of a wide range of businesses, be they technological or agricultural. Barclays Asset and Sales Finance [http://www.business.barclays.co.uk/BRC1/jsp/brccontrol?site=bbb&task=channelFWgroup&value=7148], for instance, offer a Technology Lease asset finance product to help finance your technology needs, as well as an Agricultural Lease, which offers finance to buy machinery, vehicles and land, as well as many other benefits. So if you’re planning to start up a business, or you run an established business in need of asset and sales financing products, check out your bank’s asset and sales financing solutions to see what difference they can make.

S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength

Your stocks to watch for the week ahead are Cheniere Energy (LNG), S&P 500 biotech giant Vertex Pharmaceuticals (VRTX), Cardinal Health (CAH), Steel Dynamics (STLD) and Genuine Parts (GPC).

X
While the market remains in correction, with analysts and investors wary of an economic downturn, these five stocks are worth adding to watchlists. S&P 500 medical giants Vertex and Cardinal Health have been holding up, as health-care related plays tend to do well in down markets.

Steel Dynamics and Genuine Parts are both coming off strong earnings as both the steel and auto parts industries report optimistic outlooks. Meanwhile, Cheniere Energy saw sales boom in the second quarter as demand in Europe for natural gas continues to grow.

Major indexes have been making rally attempts with the Dow Jones and S&P 500 testing weekly support on Friday. With market uncertainty, investors should be ready for follow-through day breakouts and keep an eye on these stocks.

Cheniere Energy, Cardinal Health and VRTX stock are all on IBD Leaderboard.

Cheniere Energy Stock
LNG shares rose 1.1% to 175.79 during Friday’s market trading. On the week, the stock advanced 3.1%, not from highs, bouncing from its 21-day and 10-week lines earlier in the week.

Cheniere Energy has been consolidating since mid-September, but needs another week to forge a proper base, with a potential 182.72 buy point formed on Aug. 10.

Houston-based Cheniere Energy was IBD Stock Of The Day on Thursday, as the largest U.S. producer of liquefied natural gas eyes strong demand in Europe.

Even though natural gas prices are plunging in the U.S. and Europe, investors still see strong LNG demand for Cheniere and others.

The U.K. government confirmed last week that it is in talks for an LNG purchase agreement with a number of companies, including Cheniere.

In the first half of 2021, less than 40% of Cheniere’s cargoes of LNG landed in Europe. That jumped to more than 70% through this year’s second quarter, even as the company ramped up new export capacity. The urgency of Europe’s natural gas shortage only intensified last month. That is when an explosion disabled the Nord Stream 1 pipeline from Russia that had once supplied 40% of the European Union’s natural gas.

In Q2, sales increased 165% to $8 billion and LNG earned $2.90 per share, up from a net loss of $1.30 per share in Q2 2021. The company will report Q3 earnings Nov. 3, with investors seeing booming profits for the next few quarters.

Cheniere Energy has a Composite Rating of 84. It has a 98 Relative Strength Rating, an exclusive IBD Stock Checkup gauge for share price movement with a 1 to 99 score. The rating shows how a stock’s performance over the last 52 weeks holds up against all the other stocks in IBD’s database. The EPS rating is 41.

Vertex Stock
VRTX stock jumped 3.4% to 300 on Friday, rebounding from a test of its 50-day moving average. Shares climbed 2.2% for the week. Vertex stock has formed a tight flat base with an official buy point of 306.05, according to MarketSmith analysis.

The stock has remained consistent over recent weeks, while the relative strength line has trended higher. The RS line tracks a stock’s performance vs. the S&P 500 index.

Vertex Q3 earnings are on due Oct. 27. Analysts see EPS edging up 1% to $3.61 per share with sales increasing 16% to $2.2 billion, according to FactSet.

The Boston-based global biotech company dominates the cystic fibrosis treatment market. Vertex also has other products in late-stage clinical development that target sickle cell disease, Type 1 diabetes and certain genetically caused kidney diseases. That includes a gene-editing partnership with Crispr Therapeutics (CRSP).

In early August, Vertex reported better-than-expected second-quarter results and raised full-year sales targets.

S&P 500 stock Vertex ranks second in the Medical-Biomed/Biotech industry group. VRTX has a 99 Composite Rating. Its Relative Strength Rating is 94 and its EPS Rating is 99.

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Cardinal Health Stock
CAH stock advanced 3.2% to 73.03 Friday, clearing a 71.22 buy point from a shallow cup-with-handle base and hitting a record high. But volume was light on the breakout. CAH stock leapt 7.3% for the week.

Cardinal Health stock’s relative strength line has also been trending up for months.

The cup-with-handle base is part of a base-on-base pattern, forming just above a cup base cleared on Aug. 11.

Cardinal Health, based in Dublin, Ohio, offers a wide assortment of health care services and medical supplies to hospitals, labs, pharmacies and long-term care facilities. The company reports that it serves around 90% of hospitals and 60,000 pharmacies in the U.S.

S&P 500 stock Cardinal Health will report Q1 2023 earnings on Nov. 4. Analysts forecast earnings falling 26% to 96 cents per share. Sales are expected to increase 10% to $48.3 billion, according to FactSet.

Cardinal Health stock ranks first in the Medical-Wholesale Drug/Supplies industry group, ahead of McKesson (MCK), which is also showing positive action. CAH stock has a 94 Composite Rating out of 99. It has a 97 Relative Strength Rating and an EPS rating of 73.

Steel Dynamics Stock
STLD shares shot up 8.5% to 92.92 on Friday and soared 19% on the week, coming off a Steel Dynamics earnings beat Wednesday night.

Shares blasted above an 88.72 consolidation buy point Friday after clearing a trendline Thursday. STLD stock is 17% above its 50-day line, definitely extended from that key average.

Steel Dynamics’ latest consolidation could be seen as part of a larger base going back six months.

Steel Dynamics topped Q3 earnings views with EPS rising 10% to $5.46 while revenue grew 11% to $5.65 billion. The steel producer’s outlook is optimistic despite weaker flat rolled steel pricing. STLD reports its order activity and backlogs remain solid.

The Fort Wayne, Indiana-based company is among the largest producers of carbon steel products in the U.S. It engages in metal recycling operations along with steel fabrication and produces myriad steel products.

How Millett Grew Steel Dynamics From A Three Employee Business

STLD stock ranks first in the Steel-Producers industry group. STLD stock has a 96 Composite Rating out of 99. It has a 90 Relative Strength Rating, an exclusive IBD Stock Checkup gauge for share-price movement that tops at 99. The rating shows how a stock’s performance over the last 52 weeks holds up against all the other stocks in IBD’s database. The EPS rating is 98.

Genuine Parts Stock
GPC stock gained 2.8% to 162.35 Friday after the company topped earnings views with its Q3 results on Thursday. For the week GPC advanced 5.1% as the stock held its 50-day line and is in a flat base.

GPC has an official 165.09 flat-base buy point after a three-week rally, according to MarketSmith analysis.

The relative strength line for Genuine Parts stock has rallied sharply to highs over the past several months.

On Thursday, the Atlanta-based auto parts company raised its full-year guidance on growth across its automotive and industrial sales.

Genuine Parts earnings per share advanced 19% to $2.23 and revenue grew 18% to $5.675 billion in Q3. GPC’s full-year guidance is now calling for EPS of $8.05-$8.15, up from $7.80-$7.95. The company now forecasts revenue growth of 15%-16%, up from the earlier 12%-14%.

During the Covid pandemic, supply chain constraints caused a major upheaval in the auto industry, sending prices for new and used cars to record levels. This has made consumers more likely to hang on to their existing vehicles for longer, driving mileage higher and boosting demand for auto replacement parts.

Fellow auto stocks O’Reilly Auto Parts (ORLY) and AutoZone (AZO) have also rallied near buy points amid the struggling market. O’Reilly reports on Oct. 26.

IBD ranks Genuine Parts first in the Retail/Wholesale-Auto Parts industry group. GPC stock has a 96 Composite Rating. Its Relative Strength Rating is 94 and it has an EPS Rating of 89.